Ustekinumab does not increase tuberculosis risk: Results from a national database in South Korea

J Am Acad Dermatol. 2020 May;82(5):1243-1245. doi: 10.1016/j.jaad.2019.12.033. Epub 2019 Dec 20.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Child
  • Dermatologic Agents / adverse effects*
  • Female
  • Humans
  • Incidence
  • Interleukin-12 / antagonists & inhibitors
  • Interleukin-12 / immunology
  • Interleukin-23 / antagonists & inhibitors
  • Interleukin-23 / immunology
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Republic of Korea / epidemiology
  • Risk Assessment
  • Tuberculosis / epidemiology*
  • Tuberculosis / immunology
  • Ustekinumab / adverse effects*
  • Young Adult

Substances

  • Dermatologic Agents
  • Interleukin-23
  • Interleukin-12
  • Ustekinumab